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Clostridium perfringens enterotoxin is a common cause of
food-borne and antibiotic-associated diarrhea. The toxin’s
receptors on intestinal epithelial cells include claudin-3 and -4,
members of a large family of tight junction proteins. Toxin-in-
duced cytolytic pore formation requires residues in the NH2-
terminal half, whereas residues near the COOH terminus are
required for binding to claudins. The claudin-binding COOH-
terminal domain is not toxic and is currently under investiga-
tion as a potential drug absorption enhancer. Because claudin-4
is overexpressed on some human cancers, the toxin is also being
investigated for targeting chemotherapy. Our aim was to solve
the structure of the claudin-binding domain to advance its ther-
apeutic applications. The structure of a 14-kDa fragment con-
taining residues 194 to the native COOH terminus at position
319was solved by x-ray diffraction to a resolution of 1.75 Å. The
structure is a nine-strand  sandwich with previously unappre-
ciated similarity to the receptor-binding domains of several
other toxins of spore-forming bacteria, including the collagen-
binding domain of ColG from Clostridium histolyticum and
the large Cry family of toxins (including Cry4Ba) of Bacillus
thuringiensis. Correlations with previous studies suggest that
the claudin-4 binding site is on a large surface loop between
strands 8 and 9 or includes these strands. The sequence
that was crystallized (residues 194–319) binds to purified
human claudin-4 with a 1:1 stoichiometry and affinity in the
submicromolar range similar to that observed for binding of
native toxin to cells. Our results provide a structural frame-
work to advance therapeutic applications of the toxin and
suggest a common ancestor for several receptor-binding
domains of bacterial toxins.
Enterotoxin-positiveClostridiumperfringens typeA is one of
the most common food poisoning agents in the United States;
among the several toxins it produces is C. perfringens entero-
toxin (CPE).3 CPE has also been implicated in antibiotic-asso-
ciated diarrhea in humans and is an important cause of gastro-
intestinal illness in domestic animals (1). CPE binds to human
ileal epithelium,where it induces fluid and electrolyte loss along
with epithelial cell necrosis (2). CPE cytotoxicity is a multistep
process that initiates with CPE binding to an extracellular loop
on specificmembers of the large claudin family of tight junction
proteins (3, 4). This is followed by formation of SDS-resistant
complexes of 450 and 600 kDa, which contains CPE and
claudins; the 600-kDa complex also contains a second tight
junction transmembrane protein, occludin (5, 6). These large
complexes are thought to represent the cytotoxic pores, which
create a hole in the plasmamembrane and lead to cell death (7).
The structure of CPE remains unknown, and this has slowed
a more detailed understanding of its complex pathogenic
mechanism.
The 35-kDa CPE toxin lacks primary sequence homology to
any identified bacterial proteins, except for limited similarity
(of unknown functional significance) between the NH2-termi-
nal two-thirds of CPE and some Clostridium botulinum pro-
teins. CPE has been functionally divided into two major
domains, with the NH2-terminal half responsible for toxicity
and the COOH-terminal half containing the claudin-binding
sequences (8) (Fig. 1A). Exposure to trypsin or chymotrypsin
removes a putative prosequence resulting in a 2–3-fold increase
in toxicity. The sequences sufficient for binding to cells and to
claudins are located within the COOH-terminal 30 residues.
Removal of these residues eliminates binding, and a fusion pro-
tein containing only these residues can compete for binding
with full-length CPE to isolated brush border membranes (9).
In other studies, removal of the last 5 amino acids was sufficient
to completely abrogate binding (8) (Fig. 1A), although it
remains unclearwhether these residues contain the binding site
or if their removal destabilizes the protein.
Although the COOH-terminal half of CPE, C-CPE, is not
cytotoxic, it does have distinct effects on the tight junction bar-
rier of epithelia. For example, exposure of cultured Madin-
Darby canine kidney cell epitheliamonolayers to C-CPE-(184–
319) results in a reversible decrease in transepithelial electrical
resistance and increase in paracellular permeability for
uncharged solutes (4). This is accompanied by a selective loss of
claudin-4, whereas the levels and distribution of claudins that
do not bind CPE are unaffected. The selective removal of spe-
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cific claudins from the tight junction appears to be a different
mechanism thanCPE-induced toxicity, since the former is slow
and reversible and does not affect plasma membrane integrity,
whereas CPE-induced toxicity is associated with increased cell
membrane permeability and is not reversible. This has led to
investigation of C-CPE as an agent to enhance transepithelial
drug absorption (10).
CPE is also being investigated in cancer diagnosis and as a
potential cancer chemotherapeutic agent. A large number of
recent studies document dramatic up-regulation of the CPE
receptors, claudin-3 and/or claudin-4, inmanypancreatic ovar-
ian, breast, and uterine cancers (reviewed by Morin (11)). For
example, injections of CPE into pancreatic tumors induced in
nude mice resulted in tumor necrosis and significant reduc-
tions in tumor growth (12). Injection of CPE into the perito-
neum of mice seeded with human ovarian cancer cells elimi-
nated the malignant cells (13). In other studies, intracranial
CPE administration inhibited tumor growth and increased sur-
vival in two murine models of breast cancer brain metastasis
(14).
In the current study, we determined the structure of the
COOH-terminal domain of CPE, residues 194–319, which
approximates the C-CPE domain used for functional studies by
others and includes the claudin-binding site. The structure of
C-CPE-(194–319) is a 9-strand -sandwich and allows us to
rationalize results of the claudin-binding studies. Structural
similarity algorithms reveal previously unappreciated struc-
tural and sequence homology to the receptor-binding domains
located at the COOH termini of several other toxins from
spore-forming bacteria, suggesting a commonorigin. Availabil-
ity of the structure of C-CPE-(194–319) will accelerate its ther-
apeutic applications in cancer chemotherapy and drug delivery.
EXPERIMENTAL PROCEDURES
Oligonucleotides were synthesized by Invitrogen, and DNA
was sequenced at the Genome Analysis Core of the University
of North Carolina Lineberger Comprehensive Cancer Center.
Crystallography and structural studies were performed in the
University of North Carolina Biomolecular X-ray and Struc-
tural Bioinformatics Cores.
Protein Expression and Purification
CPE Fragments—Sequences encoding C-CPE-(194–319)
were amplified by PCR fromC-CPE-(168–319) using the oligo-
nucleotide primers 5-GGGAATTCGGCgatatagaaaaagaaatcc-
ttgatttagctgctgc and 5-GTGGAAATTACCCTTATTCAAT-
ATTATTTCAAAAATTTTAATAAGCTTG and cloned into
the EcoRI and HindIII sites of pMAL K4 (15) and expressed in
Escherichia coli strainDH5 cells. Following inductionwith 0.3
mM isopropyl 1-thio--D-galactopyranoside, bacteria were
lysed by sonication in phosphate-buffered saline with protease
inhibitor tablets (Complete Mini, EDTA-free; Roche Applied
Science) and 1 mM phenylmethylsulfonyl fluoride, and insolu-
ble material was removed by centrifugation at 10,000 g for 15
min at 4 °C.MBP-C-CPE-(194–319) was affinity-purified from
the soluble fraction with cobalt resin (Talon Superflow metal
affinity resin; Clontech); purified protein was eluted with 150
mM imidazole in 10 mM Hepes, 120 mM NaCl, pH 7.4. C-CPE-
(194–319) was cleaved from MBP by overnight digestion with
thrombin (Sigma); after the addition of 1 mM phenylmethylsul-
fonyl fluoride, thrombin was removed by adsorption to para-
aminobenzamidine-agarose (Sigma). C-CPE-(194–319) was
separated from cleavedMBP by size exclusion chromatography
on aHi-Prep Sephacryl S-100 column (1.6 60 cm;GEHealth-
care) in 10 mM Hepes, 120 mM NaCl; C-CPE-(194–319)-con-
taining fractions were concentrated to 10 mg/ml using first a
Centriplus then Centricon concentrator. Concentrated protein
was clarified by centrifugation at 100,000  g for 20 min and
used for crystallization trials; purity was assessed by
SDS-PAGE.
Claudin-4—Full-length human claudin-4 with an NH2-ter-
minal His10 tag was expressed in Sf9 baculovirus cells and puri-
fied as previously described (16) with the following modifica-
tions. Frozen cell pellets were thawed and washed once in
phosphate-buffered saline and then resuspended in 10 mM
Hepes, pH 7.4, 120 mM NaCl with protease inhibitor tablets
(CompleteMini, EDTA-free, RocheApplied Science) and 1mM
phenylmethylsulfonyl fluoride, 20 units/ml DNase I. Cells were
sonicated briefly, dodecylmaltoside (Anatrace, Manumee, OH)
was added to 2%, and sample was incubated at 90 min at room
temperature with gentle mixing. Insoluble material was
removed by centrifugation at 30,000  g for 40 min, and super-
natant was incubated with Co2 resin (Talon) overnight. Resin
was washed with 10 mM imidazole, 10 mM Hepes, pH 7.4, 120
mM NaCl, 5 mM dodecylmaltoside, and eluted in the same
buffer with 150 mM imidazole. Claudin-4 was further purified
by size exclusion chromatography on a Superdex S200 column
(1 30 cm; GEHealthcare), and peak fractions were70–90%
pure (different preparations) based on SDS-PAGE and Coo-
massie Blue staining. Based on column calibration with
molecular weight standards, recombinant claudin-4 elutes at
a size consistent with a monomer (15.2 kDa) associated with
a DDM micelle (average micelle mass of 50 kDa). For some
binding assays, claudin-4 was further purified by rebinding
to and re-elution from metal affinity resin after size exclu-
sion chromatography.
Binding Assays
To measure the interaction between bacterially produced
C-CPE-(194–319) and claudin-4 purified from insect cells,
His-tagged claudin-4 was immobilized on cobalt affinity
resin (Talon), and aliquots of 50 l of beads (5 M claudin-4)
were incubated with 0.5–20 M purified C-CPE-(194–319)
overnight at 4 °C in 10 mM Hepes, pH 7.4, 120 mM NaCl, 5
mM dodecylmaltoside. Beads were washed four times in
binding buffer and eluted with binding buffer containing 150
mM imidazole. Eluted material was diluted in SDS-sample
buffer, resolved by SDS-PAGE, and detected by Coomassie
Brilliant Blue staining. Relative protein levels were quanti-
fied using a Licor Odyssey infrared imaging system (Licor
Biosciences, Lincoln, NE); binding assays were repeated
twice. Binding curves were analyzed by nonlinear regression
assuming a single binding site using Prizm software (Graph-
Pad, San Diego, CA).
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Crystallization
Crystallization conditions were screened at 4 °C and room
temperature using hanging drop vapor diffusion (17) and a
commercially available screen (Salt Rx; Hampton Research,
Aliso Viejo, CA); small crystals were used to make microseed
stocks. Crystals used in analysis were obtained bymixing 2l of
protein solution at 10mg/ml, 2l of reservoir solution contain-
ing 0.1MTris, pH8.3, 0.8M lithium sulfate, 20%glycerol, and 0.5
l of microseed solution and allowing the drop to equilibrate
against 0.7 ml of reservoir solution using the sitting drop
method. Crystals were flash-cooled in liquid nitrogen with
cryo-oil (Hampton Research) as cryoprotectant, and all data
sets were collected at 100 K (nitrogen stream).
Data Collection, Phasing, and Refinement
The structure was solved by single wavelength anomalous
dispersion, using the short halide soak derivatizationmethod of
Dauter et al. (18). The crystal used for the NaI soak was har-
vested from its growth drop and soaked for 60 s in a 2.0-l drop
of its mother liquor to which NaI was added to 0.8 M. Data were
collected at CuK at the University of North Carolina Biomo-
lecular X-ray Crystallography Facility on an R-Axis IV
Image plate. The one sodium iodide-soaked crystal had a dif-
ferent unit cell (same space group, P212121), whereby the a axis
was reduced by about 8 Å, the c axis was increased by about 12
Å, and the b axis was increased by about 2 Å.
The change in unit cell in the NaI-soaked crystal results in
completely different packing interfaces and a slight shrinkage
(3.6%) in unit cell volume. The NH2 terminus points in a differ-
ent direction with respect to the main C-CPE fold in the two
crystal forms; however, this segment does not have iodide ions
bound in the NaI soak, which might have explained the slightly
different directions. As expected, there are iodide ions bound to
the surface of the protein and participating in packing interac-
tions in the soaked crystal, which could explain the unit cell
rearrangement. It is also possible that the two unit cell packing
arrangements are present in native crystals, and we happened
to select the different form for the NaI quick soak, but it seems
more likely that the rearrangement was caused by the soak.We
did not collect data from any other native crystals, but since the
structure of the protein is the same (except for the first 7 amino
acids, which are not part of the COOH-terminal sandwich) in
the two forms, this observation is not biologically relevant.
Iodide ion sites were found by SHELXD (19) using data to
2.2 Å (three major sites, SHELXD CC  40.96 all/22 weak).
Solvent-flattened maps created by SHELXE were of excellent
quality, such that the ArpWarp (20) automatic chain tracing
program could place 112 of 126 of the amino acids of C-CPE-
(194–319) correctly. Manual model rebuilding was carried out
with COOT (21), and all but the first four amino acids are well
ordered (these are at the NH2 terminus of the construct). The
model from the iodide soak unit cell was placed into the native
unit cell using the molecular replacement program PHASER
(22); waters were located, and the model was adjusted with
COOT, and then refinement was carried out using Refmac
from the CCP4 (23). Final refinement used the native crystal
data, because the signal-to-noise ratio was higher in all resolu-
tion shells than the iodide-soaked crystal. The final model has
good stereochemistry and Rfree of 22.7%.
RESULTS AND DISCUSSION
C-CPE-(194–319) Binds to Claudin-4 with High Affinity and
a 1:1 Stoichiometry—Our long term goal is to understand how
CPE andC-CPE interact with their cellular receptors, which are
a subset of the large claudin family. The full-length toxin tends
to aggregate after purification; consequently, we initially
expressed, purified, and attempted to crystallize the previously
characterized C-CPE-(168–319) fragment (Fig. 1A). This frag-
ment is known to contain the claudin-binding region within
residues 290–319.We found that this fragment is also unstable
and oligomerizes upon storage at high concentration. By pro-
gressive deletion, we identified a fragment containing residues
FIGURE 1. Functional organization of the C. perfringens enterotoxin and
binding of C-CPE-(194 –319) to human claudin-4. A, residues 1–168 have
been referred to as N-CPE (NH2-terminal), and 168 –319 have been referred to
as C-CPE. Residues within the range 47–51 are required for cytotoxicity via
induction of a complex of tight junction proteins to form a transmembrane
pore. Removal of residues 290 –319 destroys claudin-binding, and a fragment
290 –319 can itself compete with CPE in cell surface binding assays. B, C-CPE-
(194 –319) binds with 1:1 stoichiometry and submicromolar affinity to pure
claudin-4. A fixed concentration of His10-claudin-4 (5 M) was immobilized on
Co2 beads and mixed with increasing concentrations of purified C-CPE-
(194 –319) (0 –20 M). The bound C-CPE was resolved by SDS-PAGE and
stained with Coomassie Brilliant Blue. There was no detectable binding of
C-CPE-(194 –319) to Co2 beads alone (not shown). Saturation binding curves
of C-CPE-(194 –319) to His10-claudin-4. Known concentrations of C-CPE and
His10-claudin-4 were loaded on the same gel to confirm the linearity of Coo-
massie binding. C, binding curves were plotted using nonlinear regression
analysis of the scanned Coomassie gel and are representative of two similar
experiments; Kd  0.60 and 0.65 M in independent experiments. Saturation
occurred at 1:1 stoichiometry.
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194–319, which is highly stable and a monomer as determined
by gel exclusion chromatography. In order to determine
whether this fragment retained the ability to bind to claudin-4,
we performed binding studies using purified His10-tagged
human claudin-4 immobilized on Co2 resin. Binding satu-
rated with a 1:1 stoichiometry and Kd in the submicromolar
range (Fig. 1, B and C). This high affinity is similar to that pre-
viously reported for C-CPE-(168–319) binding to claudin-ex-
pressing cultured cells (24), and we conclude that C-CPE-
(194–319) is an appropriate fragment of CPE for structural
analysis.
Structure of C-CPE-(194–319)—The structure of C-CPE-
(194–319) was solved to 1.75 Å resolution using single wave-
length anomalous dispersion and the short halide soak deri-
vatization method of Dauter et al. (17). The final model has
good stereochemistry and Rfree of 22.7%. A full summary of
data collection, phasing, and refinement statistics is
included in Table 1.
C-CPE-(194–319) forms a nine-strand  sandwich with a
short helical element between strands 1 and 2 (Fig. 2). Adja-
cent strands within each sheet have antiparallel orientations
except for the uncommon parallel alignment of strands 1 and
3 (Figs. 2 and 3). The NH2-terminal seven residues, which are
structured, interact with water molecules and not the main 
sandwich, suggesting that the minimal C-CPE domain is
formed by residues Ala205 through the COOH terminus at
Phe319. This should assist future efforts aimed at producing
a more solute and stable C-CPE domain for therapeutic
application.
The claudin-binding region is known to be within the
COOH-terminal 30 residues (25), which corresponds to
strands 8 and 9, each positioned in the center of the
opposing  sheets, and the intervening surface loop span-
ning residues Lys304–Tyr312. This region is highlighted in
dark blue in Fig. 2. Deletion of the COOH-terminal 30 resi-
dues eliminates claudin binding (8). However, given the cen-
tral position of strands 8 and 9, this manipulation may
severely destabilize the overall structure, thus raising con-
cerns about the interpretation of these binding studies. In
contrast, a fusion protein encoding the same sequence can
compete with native CPE for binding to cells, implicating
residues in this region as the claudin-binding site. Further-
more, mutagenesis studies more specifically implicate the
large surface loop between 8 and 9 in claudin binding (26).
Single mutations of Tyr306, Tyr310, or Tyr312 to Ala all reduce
claudin binding, whereas double mutants of Tyr306 with
either of the other tyrosines eliminates binding (Fig. 2).
Tyr306 and Tyr312 are buried under the loop; we speculate
that their mutation will distort presentation of the loop sur-
face but probably not disrupt the overall  sandwich fold or
surface residues on strands 8 and 9. Mutation of Tyr306 to
phenylalanine, also large and more hydrophobic, did not
interfere with claudin binding, whereas mutation to the
FIGURE 2. Structure of C-CPE-(194 –319). The structure is a  sandwich with
antiparallel orientations except for the uncommon parallel orientation of
adjacent strands 1 and 3. The binding site for claudin is within the COOH-
terminal 30 residues (dark blue), including strands 8 and 9 and the inter-
vening surface loop. Mutagenesis of Tyr306, Tyr310, and Tyr316 was previously
shown (26) to interfere with binding to claudin.
TABLE 1
Summary of data collection, phasing, and refinement statistics
Data collection
C-CPE
Native NaI fast soak
Wavelength (Å) 1.5418 1.5418
Resolution range (Å) 40–1.75 40–1.75
No. of measured reflections 111,494 248,626
No. of unique reflections 13,415 13,002
Redundancy (last shell) 3.8 (3.6) 7.5 (5.3)
Completeness (last shell) (%) 99.7 (98.2) 99.6 (97.7)
I/ (last shell) 33 (7) 23 (2.4)
Rsym (last shell) (%) 4.0 (18.5) 9.3 (56.9)
Space group P212121 P212121
a (Å) 37.6 29.6
b (Å) 49.0 50.8
c (Å) 69.1 82.0
No. of molecules in asymmetric unit 1 1
Phasing and refinement
Figure of merit from experimental phasing
(iodide derivative)
0.65
Resolution range (Å) 40–1.75
Rwork/Rfree (%) 19.7 (22.9)
No. of reflections for refinement 12,749
No. of reflections for test set (%) 663 (5%)
No. of protein residues/non-hydrogen atoms 126 (1218)
No. of water molecules 213
Bond lengths (root mean square deviations in
Å relative to ideal values)
0.007
Bond angles (root mean square deviations in
degrees relative to ideal values)
1.296
Residues in favored regions (%) 94
Residues in additionally allowed regions (%) 6
Residues in generously allowed/disallowed
regions (%)
0
Average atomic B-factor protein atoms
(water atoms)
11.7 (30)
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charged residue lysine eliminated binding (27). Knowledge
of the structure suggests very direct mutagenesis studies to
define the claudin-binding residues without disrupting the
overall domain fold; further identification of these residues
and their folding context could lead to development of pep-
tidomimetics with claudin-binding activity. Strands 8 and
9 and especially the large intervening surface loop are
attractive sequences for future investigation of claudin-tar-
geting strategies.
The C-CPE-(194–319) Structure
Reveals Unexpected Similarity to
the Receptor-binding Domains of
Other Bacterial Toxins—C-CPE-
(194–319) lacks convincing primary
sequence homology to domains of
any other bacterial toxin when sub-
jected to standard BLAST searching
and is thought to be biologically
unique. However, a search for simi-
lar three-dimensional structures
using the DALI (Z-score) and root
mean square (DRMS) similarity algo-
rithms (28) revealed structural sim-
ilaritywith domains ofmore than 10
bacterial toxins. We highlight two
examples that have striking biologi-
cal analogy to C-CPE-(194–319)
despite the initial absence of obvi-
ous sequence homology, namely
domains within the ColG collagen-
ase of Clostridium histolyticum (29)
(Z-score 9.1,DRMS  2.9) and the
Cry4Ba toxin ofBacillus thuringien-
sis (30) (Z-score 6.5,DRMS  3.8).
Inboth cases, the similarity iswith the
14-kDaCOOH-terminaldomainof
the toxin/enzyme,which, likeC-CPE-
(194–319), functions in receptor
binding by these toxins. Both are sandwiches that share a similar
secondary structure topology with C-CPE-(194–319). This
includes the same relationship among strands in each sheet, 6-5-
8-3-1 on one side and 2-9-4-7 on the other, and the unusual par-
allel orientation of strands1 and3, noted in Fig. 3.Ribbonmod-
els of the three domains are oriented in Fig. 3 to optimize
alignment of the secondary structure elements.
Primary sequence homology can be identifiedwithin the cor-
responding  strands after first aligning residues that are
FIGURE 3. The topology of the ligand-binding domains of C-CPE-(194 –319), ColG, and Cry4Ba are similar. The nine  strands (blue) of C-CPE-(194 –319)
are numbered from the amino end with strands 6-5-8-3-1 and 2-9-4-7 positioned on opposing sheets. Adjacent strands are antiparallel except for the
uncommon parallel orientation of strands 3 and 1. This signature topology is shared by the receptor-binding domains of ColG and Cry4Ba. Surface loops are
colored red. The short helix between 1 and 2 in C-CPE-(194 –319) and three short  strands in Cry4Ba between 2 and 3, which are not part of the 
sandwich, are removed in this presentation. Structures are oriented to optimize alignment of secondary structure elements using PRGOGRAM.
FIGURE 4. Sequence homology is detected at analogous structural positions along the corresponding
strands of C-CPE-(194 –319), ColG, and Cry4Ba. The three sequences are aligned at residues that share
analogous three-dimensional structural positions along each strand (blue), as detected by the Insight II algo-
rithm. Amino acid similarities (dots) and identities (double dots) are observed at analogous structural positions
within most strands. Searching for sequence homology with ClustalW results in alignment of some (boxed) but
not all structurally analogous positions. CPE contains an -helical segment between 1 and 2; Cry4Ba con-
tains three  strands between strands 2 and 3, which are not part of the nine-strand  sandwich.
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located at analogous three-dimensional positions, using the
Insight II algorithm (Accelrys Software Inc.). Alignment of
homologous positions within the three sequences is presented
in Fig. 4 with residues within each strand colored blue. Interest-
ingly, when ClustalW is used to search for sequence homology
among the three sequences, it aligns (boxed regions of Fig. 4)
some but not all of the analogous three-dimensional positions.
For example, ClustalW will align 4 of C-CPE and Cry4Ba but
not ColG, despite ColG having chemically homologous resi-
dues at the analogous three-dimensional positions along the
strand. Sequence homology is found at analogous positions
within strands 3, 4, 5, 7, 8, and 9. Strands 1, 2, and 6, which are
on the periphery of the sheets, are not as clearly related, perhaps
suggesting conservation of interactions within but not at the
edges of the sandwich. We speculate that these receptor-bind-
ing domains share an evolutionary origin because of their sim-
ilar folds, sequence homology at corresponding structural posi-
tions, and biological activities. Others have noted that 
sandwich domains are common in receptor-binding domains
for both microbial and eukaryotic proteins (31, 32).
C. histolyticum is an anaerobic spore-forming bacterium that
causes gas gangrene and produces collagenases that lead to exten-
sive tissue destruction. The mature enzyme class I collagenase
fromC.histolyticum is composedof anNH2-terminalmetallopro-
teasedomain, a spacerdomain, and twocollagenbindingdomains.
The COOH-terminal binding domain not only shows structural
similarity toC-CPE-(194–319),butmutational analysisof selected
aminoacidsdemonstrates that, likeCPE, several tyrosinesnear the
extreme COOH terminus are critical for collagen binding (29).
However, these are not analogous residues, since they are exposed
to the solvent andpresent on strand8 andnot buried on the loop
between 8 and 9 like in CPE.
B. thuringiensis is also a spore-forming Gram-positive bacte-
rium. It produces a large number of insecticidal toxins stored as
crystalline (Cry) protoxins (33). In an analogous fashion toCPE,
following ingestion and activation by gut proteases, the Cry4Ba
toxin binds to specific receptors on insect gut epithelial cells.
Binding is followedby a conformational change that leads to the
formation of membrane pores in the epithelial cells and cell
lysis (33). The Cry toxins have three domains, the first of which
is the toxic/pore-forming domain, and the second two
domains, II and to a lesser extent domain III, are involved in
receptor binding (30, 34). Domain III, which has structural sim-
ilarity to C-CPE, resembles a number of carbohydrate binding
domains that are found in microbial hydrolases and esterases
(35), but specific residues known to be critical for carbohydrate
binding are not generally conserved in the domain III of Cry
toxins. Thus, the receptor binding surfaces on Cry proteins and
CPE do not appear to be analogous.
C-CPE has been reported to interact with the second extra-
cellular domain of claudins (24). However, although we could
demonstrate high affinity interactions with full-length clau-
din-3 (not shown) and claudin-4, we were unable to demon-
strate binding of purified C-CPE to either synthetic peptides or
fusion proteins comprising the second extracellular domain of
claudin-3 or claudin-4. Future investigations will focus on the
region of claudin-4 that interacts with C-CPE. In summary, the
availability of a structure for C-CPE-(194–319) suggests an
unsuspected shared origin for the receptor-binding domains of
several bacterial toxins and should allow rational modifications
of the protein for future therapeutic applications.
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